Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | PAK4 | O96013 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177427 | 0.91 | HRH4 (0.63) | SMN1; SMN2HRH4CYP2D6CYP2C19PIK3CB | |
| SCHEMBL18177442 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2HRH4CYP2D6CYP2C19PIK3CB | |
| SCHEMBL10330161 | 0.84 | HRH4 (0.51) | SMN1; SMN2HRH4CYP2D6CYP2C19PIK3CB | |
| SCHEMBL12122637 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2HRH4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7284762 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2HRH4PIK3CBALDH1A1AURKA | |
| SCHEMBL5153294 | 0.84 | HRH4 (0.57) | SMN1; SMN2HRH4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL9884921 | 0.83 | DAPK3 (0.56) | SMN1; SMN2ALDH1A1AURKADAPK3JAK2 | |
| SCHEMBL7653540 | 0.83 | ALDH1A1 (0.53) | SMN1; SMN2HRH4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1321129 | 0.81 | HRH4 (0.60) | SMN1; SMN2HRH4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL12322288 | 0.81 | DAPK3 (0.61) | SMN1; SMN2CYP2D6CYP2C19ALDH1A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191774-B | Heterocyclic compound, preparation method and application thereof | 中国药科大学 | 2022-05-24 | — | — | CN | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-1066266-B1 | CYCLIN DEPENDENT KINASE INHIBITORS | CANCER REC TECH LTD (GB) | 2005-11-09 | — | — | EP | disclosed |
| US-6677345-B1 | PYRMIDINE DERIVATIVE ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-01-13 | — | — | US | disclosed |
| EP-1066266-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050251-A2 | CYCLIN DEPENDENT KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | SMN1; SMN2 4444/4885HRH4 677/4885CYP2D6 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.